Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
Standard
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice. / Langer, Florian; Gerlach, Horst E; Schimke, Alexandra; Heinken, Andreas; Hoffmann, Ulrich; Noppeney, Thomas; Pittrow, David; Klotsche, Jens; Rabe, Eberhard; Bauersachs, Rupert; INSIGHTS-SVT study group.
In: THROMB RES, Vol. 220, 12.2022, p. 145-152.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice
AU - Langer, Florian
AU - Gerlach, Horst E
AU - Schimke, Alexandra
AU - Heinken, Andreas
AU - Hoffmann, Ulrich
AU - Noppeney, Thomas
AU - Pittrow, David
AU - Klotsche, Jens
AU - Rabe, Eberhard
AU - Bauersachs, Rupert
AU - INSIGHTS-SVT study group
PY - 2022/12
Y1 - 2022/12
N2 - BackgroundDespite significant progress in the understanding of paraneoplastic deep vein thrombosis (DVT) and pulmonary embolism (PE), little is known about the outcomes of cancer-associated superficial vein thrombosis (SVT) in daily practice.MethodsINSIGHTS-SVT was a prospective observational study on patients with acute isolated SVT. Primary outcome measure was symptomatic venous thromboembolism (VTE), a composite of DVT, PE, and SVT extension/recurrence, at 3 months. Clinically relevant bleeding was also assessed.ResultsOf 1151 patients included, 6.7 % either had active cancer at baseline or were diagnosed with cancer during 12 months of follow-up. At 3 months, symptomatic VTE had occurred in 13.0 % and 5.4 % of cancer and non-cancer patients, respectively (HR 2.6, 95 % CI 1.3–5.0). Regarding secondary outcomes, cancer patients had increased risks of DVT and PE (HR 3.9, 95 % CI 1.3–11.8) and hospitalization due to VTE (HR 11.0, 95 % CI 2.5–49.0). The rate of clinically relevant bleeding was numerically higher in the cancer cohort (3.9 % vs 1.3 %, HR 3.1, 95 % CI 0.9–10.7). At 12 months, the primary composite outcome had occurred in 15.6 % and 11.9 % of cancer and non-cancer patients, respectively (HR 1.9, 95 % CI 1.0–3.5). After adjusting for additional risk factors, including age, history of DVT/PE and cardiovascular risk factors/diseases, the association of cancer with the primary outcome remained statistically significant.ConclusionCancer patients with isolated SVT are at significant risk of symptomatic VTE. While most events occur within 3 months, the VTE risk remains elevated up to one year of follow-up.
AB - BackgroundDespite significant progress in the understanding of paraneoplastic deep vein thrombosis (DVT) and pulmonary embolism (PE), little is known about the outcomes of cancer-associated superficial vein thrombosis (SVT) in daily practice.MethodsINSIGHTS-SVT was a prospective observational study on patients with acute isolated SVT. Primary outcome measure was symptomatic venous thromboembolism (VTE), a composite of DVT, PE, and SVT extension/recurrence, at 3 months. Clinically relevant bleeding was also assessed.ResultsOf 1151 patients included, 6.7 % either had active cancer at baseline or were diagnosed with cancer during 12 months of follow-up. At 3 months, symptomatic VTE had occurred in 13.0 % and 5.4 % of cancer and non-cancer patients, respectively (HR 2.6, 95 % CI 1.3–5.0). Regarding secondary outcomes, cancer patients had increased risks of DVT and PE (HR 3.9, 95 % CI 1.3–11.8) and hospitalization due to VTE (HR 11.0, 95 % CI 2.5–49.0). The rate of clinically relevant bleeding was numerically higher in the cancer cohort (3.9 % vs 1.3 %, HR 3.1, 95 % CI 0.9–10.7). At 12 months, the primary composite outcome had occurred in 15.6 % and 11.9 % of cancer and non-cancer patients, respectively (HR 1.9, 95 % CI 1.0–3.5). After adjusting for additional risk factors, including age, history of DVT/PE and cardiovascular risk factors/diseases, the association of cancer with the primary outcome remained statistically significant.ConclusionCancer patients with isolated SVT are at significant risk of symptomatic VTE. While most events occur within 3 months, the VTE risk remains elevated up to one year of follow-up.
KW - Humans
KW - Venous Thrombosis/drug therapy
KW - Neoplasms/complications
U2 - 10.1016/j.thromres.2022.10.022
DO - 10.1016/j.thromres.2022.10.022
M3 - SCORING: Journal article
C2 - 36370650
VL - 220
SP - 145
EP - 152
JO - THROMB RES
JF - THROMB RES
SN - 0049-3848
ER -